Ha-Jin Chun

Ms. Ha-Jin Chun

Ajou University Medical Center
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
YSYewon Suh
Yewon Suh
YAYoung-Mi Ah
Young-Mi Ah
HCHa-Jin Chun
Ha-Jin Chun
SLSu-Mi Lee
Su-Mi Lee
HKHyung-Sook Kim
Hyung-Sook Kim
JLJuyeun Lee
Juyeun Lee
Although specialized pharmacists have been suggested to be essential members of antimicrobial stewardship programs (ASPs), not all hospitals in Korea operate ASPs with pharmacists involved. We aimed to evaluate the association of involvement of clinical pharmacists as team members of multidisciplinary ASPs with the incidence of antimicrobial-related adverse drug events (ADEs). Five tertiary teaching hospitals participated in this retrospective cohort study. At each participating hospital, we randomly selected 1000 participants among patients who had received systemic antimicrobial agents for more than one day during the first quarter of 2017. We investigated five categories of antimicrobial-related ADEs: allergic reactions, hematologic toxicity, nephrotoxicity, hepatotoxicity, and antimicrobial-related diarrhea. Multivariate logistic regression analysis was used to evaluate the potential impact of pharmacist involvement in ASPs on the incidence of ADEs. A total of 1195 antimicrobial-related ADEs occurred in 618 (12.4%) of the 4995 patients included in the analysis. The overall rate of ADE occurrence was 17.4 per 1000 patient days. Hospitals operating ASPs with pharmacists showed significantly lower AE incidence proportions than other hospitals (8.9% vs. 14.7%; p < 0.001). Multidisciplinary ASPs that included clinical pharmacists reduced the risk of antimicrobial-related ADEs by 38% (adjusted odds ratio 0.62; 95% confidence interval 0.50–0.77). Our results suggest that the active involvement of clinical pharmacists in multidisciplinary ASPs may contribute to reduce the incidence of antimicrobial-related ADEs in hospitalized patients.

1 January 2025 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
YKYoung Rong Kim
Young Rong Kim
HCHa-Jin Chun
Ha-Jin Chun
JHJung Yeon Heo
Jung Yeon Heo
HHHakjun Hyun
Hakjun Hyun
YCYoung Hwa Choi
Young Hwa Choi
EKEun Jin Kim
Eun Jin Kim
Kim YR, et al. Yonsei Med J. 2025 Jun;66:e63. https://doi.org/10.3349/ymj.2024.0513

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JSJihye Shin
Jihye Shin
JPJi Young Park
Ji Young Park
JCJungmi Chae
Jungmi Chae
hyung-sook Kimhyung-sook Kim
hyung-sook Kim
SMSong Mi Moon
Song Mi Moon
KCKONAS Working Committee
KONAS Working Committee
Shin J, et al. J Korean Med Sci. 2024 Jul;39:e216. https://doi.org/10.3346/jkms.2024.39.e216

11 May 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
HCHa-Jin Chun
Ha-Jin Chun
HCHyeon Gyeom Choi
Hyeon Gyeom Choi
EBEUNSOOK BANG
EUNSOOK BANG
JLJang Hoon Lee
Jang Hoon Lee
YKYoung Rong Kim
Young Rong Kim
SKSo Hee Kim
So Hee Kim
Background/Objectives: This study compared the pharmacokinetic (PK)/pharmacodynamic (PD) targets of vancomycin in obese patients using two Bayesian programs to evaluate the accuracy and bias of these estimates. Additionally, population pharmacokinetics in obese patients were compared with those in the general patient population. Methods: Medical records of obese adults [body mass index (BMI) ≥ 30 kg/m2] treated with vancomycin at Ajou University Hospital between 2010 and 2017 were retrospectively reviewed. Patients with peak (Cpeak) and trough (Ctrough) concentrations were included. Vancomycin area under the plasma concentration-time curve (AUC) and Ctrough were estimated using Capcil (ver 6.31) and MwPharm (ver 2.3.1.89) software. Accuracy and bias were analyzed, and population PK parameters were evaluated. Results: A total of 149 cases were analyzed. AUC estimates from one-point sampling using Capcil were significantly lower than the reference values, whereas MwPharm produced estimates closer to the reference with higher accuracy and lower bias. Ctrough estimates from one-point sampling showed high accuracy for both programs. Obese patients exhibit lower volume of distribution, higher total body clearance, and shorter elimination half-life than the general patient population. Conclusions: Vancomycin pharmacokinetics differ in obese patients. Bayesian analysis using MwPharm showed AUC and Ctrough estimates that were closer to the reference values and exhibited lower bias than those obtained with Capcil in this dataset. These findings may support more informed dosing decisions for vancomycin in obese patients.